sclerosis improved the spasticity of patients previously treated with interferon-β. However, whether such an improvement was … translated into cost savings remained unclear. We therefore conducted a cost analysis of glatiramer acetate versus interferon … been switched from interferon-β to glatiramer acetate. Costs prior to starting glatiramer acetate (interferon-β period …

sclerosis improved the spasticity of patients previously treated with interferon-β. However, whether such an improvement was … translated into cost savings remained unclear. We therefore conducted a cost analysis of glatiramer acetate versus interferon … been switched from interferon-β to glatiramer acetate. Costs prior to starting glatiramer acetate (interferon-β period …

Background: The efficacy of combination therapy in previous non responders to interferon (IFN) monotherapy with chronic … cost-effectiveness analysis of therapeutic regimens with IFN alpha and ribavirin in previous interferon non …-effectiveness ratio of 11,767 euros per year of life gained and 6,073 euros per QALY. Conclusions: Combination therapy with interferon …